Serum levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF␣ have been found to correlate with SLE disease activity in most studies, [1] [2] [3] [4] [5] [6] suggesting that they may represent a driving force behind disease progression or pathology. In addition, certain studies have demonstrated increased production of these cytokines by peripheral blood mononuclear cell cultures spontaneously or after stimulation, suggesting that cells from these patients may have a generalized increased capacity for the production of pro-inflammatory cytokines. 3, 4, 7 Not all studies have been consistent, and one study utilizing flow cytometry of stimulated cells demonstrated decreased levels of intracellular TNF␣ in systemic lupus erythematosus (SLE) patients compared to controls. [8] [9] [10] [11] Data from murine SLE models have also been conflicting. Depending on the dose and the time of administration, TNF␣ may either exacerbate or ameliorate disease.
TNF␣ elicits its biological effect through the interaction with either the TNFR1 (p55) or TNFR2 (p75) receptors. Both receptors are members of the TNF-R superfamily which includes a number of receptors involved in cell signaling and apoptosis.
12 TNFR1 contains an intracellular protein domain known as the death domain which mediates apoptosis through interactions with TRADD, FADD, and RIP. TNFR1 has been demonstrated in mice to mediate many of the classic inflammatory functions ascribed to TNF␣. TNFR2 can also mediated apoptosis through its interactions with TRAF1 and TRAF2 and also plays an important role in the induction of NF-B. Therefore, TNFR2 may mediate either an apoptotic signal or a survival signal depending on the circumstances. TNFR2 signaling augments that of TNFR1 in some circumstances, 13 and is the primary receptor responsible for thymocyte proliferation and T cells. 14, 15 In addition to their roles as cell surface receptors, both molecules are shed from the cell membrane after proteolytic cleavage. As soluble receptors, they may act as TNF␣ antagonists. 16 Detection of increased circulating levels of these shed TNF receptors in SLE 2,17 has led to the hypothesis that they may represent a compensatory mechanism for overproduction of pro-inflammatory cytokines.
The concept that an imbalance in cytokine production and antagonism mediated by the soluble receptors is associated with SLE disease progression is relevant because clinical trials using cytokine inhibitors are being contemplated. There are data to suggest that there are genetic contributions to TNF␣ overproduction in SLE [18] [19] [20] [21] [22] [23] and the contribution of genetically mediated differences in TNFR function has been shown in a Japanese population. 24 The recent description of an SLE disease susceptibility locus identified through the study of multiplex kindreds, 25, 26 near the site (1p36.2) of the TNFR2 locus, 27 prompted an examination of a two base-pair polymorphism within the 3Ј untranslated region of the gene. This polymorphism lies about 150 bp downstream of the 3Ј end of the coding region and before the polyadenylation signal. 28 Although an evaluation of a coding region SNP polymorphism of the TNFR2 gene failed to reveal an association with SLE 29 and another study failed to reveal an association with Graves' disease, or diabetes, 30 the results from a study of Japanese SLE patients did demonstrate an association. 24 This latter study and the genetic mapping study suggested that a thorough evaluation of the question was needed. The two base-pair polymorphism reported here has the advantage of being highly polymorphic.
PCR amplification across the polymorphic site was performed according to previously published methods. 30 35 Slabeled amplification products were run on an SSCP 8% acrylamide gel (Figure 1) . Allele identification by this method was confirmed by direct sequencing of PCR products. The wild-type TNFR2*2 allele has a guanine at position 1666 and a thymine at position 1693 (Genbank entry M55994). 16 The corresponding polymorphic allele substitutes adenine and cytosine for those bases. There were no instances of single base-pair polymorphisms detected.
The gene frequency of this two base-pair polymorphism has been previously found to be 0.25 in a German control population. 30 We examined 101 Caucasoid American controls and 105 Caucasoid American SLE patients from the East Coast of the USA (Table 1 ). The gene frequency of the polymorphic TNFR2*1 allele was 0.27 in the control population and 0.30 in the SLE population (P = 0.584). We then examined whether either allele was found with increased frequency in a particular subset of SLE patients (Table 2) . Clinical data from a database on these patients was available for 98 of the patients. Over 50 clinical variables were examined, including type of 1,2 2,2 2,2 1,2 Figure 1 The TNFR2*1 and TNFR2*2 alleles are shown on this SSCP gel. renal disease, laboratory findings and historical features. The association of each of the clinical variables (within the SLE cohort) with either TNFR2*1 or TNFR2*2 was examined using Fisher's exact test. The only association to reach statistical significance was an association of the wild-type allele with oral contraceptive use. This is of no clinical significance, however. Selected examples are shown in Table 2 .
This study addressed whether a particular polymorphism in the TNFR2 gene was associated with SLE. This study was based on previous data demonstrating an effect of a TNF␣ ligand polymorphism with SLE, [18] [19] [20] [21] [22] [23] in vitro data suggesting over-production of TNF␣ by SLE patients, 3, 4, 7, 31, 32 and the identification of a putative disease susceptibility locus at 1p32.1, near the TNFR2 locus. 25 Failure to identify an association of this polymorphism with SLE suggests several possibilities. TNFR2 may be important in the development of SLE, however, this particular polymorphism may not be associated with any biological differences in expression or function of TNFR2. Alternatively, TNFR2 may not be relevant in the etiology or pathophysiology of SLE. It is possible that the identification of the locus at 1p32.1 is detecting a different genetic effect unrelated to TNFR2. Finally, this study examined only Caucasoid patients. It is possible that there is a TNFR2 effect in other populations. 
